GlobalData on MSN4d
MSD halts Winrevair trial due to success of previous study
MSD said that its sotatercept steering committee called for the trial to end as patients are moved to the ongoing open-label ...
Daily3d
Merck to stop trial evaluating Winrevair early in pulmonary arterial hypertension
Rahway: Merck, known as MSD outside of the United States and Canada, has announced the Phase 3 HYPERION study evaluating ...
PharmiWeb3d
Merck Announces Decision to Stop Phase 3 HYPERION Trial Evaluating WINREVAIR™ (sotatercept-csrk) Early and Move to Final Analysis
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today the Phase 3 HYPERION study evaluating WINREVAIR (sotatercept-csrk) versus placebo (both in combination with ...
Pharmabiz3d
Merck to stop phase 3 HYPERION trial evaluating Winrevair early and move to final analysis
Merck to stop phase 3 HYPERION trial evaluating Winrevair early and move to final analysis: Rahway, New Jersey Friday, January 31, 2025, 10:00 Hrs [IST] Merck, known as MSD outsid ...
Le Lézard4d
Merck Announces Decision to Stop Phase 3 HYPERION Trial Evaluating WINREVAIRtm (sotatercept-csrk) Early and Move to Final Analysis
Merck , known as MSD outside of the United States and Canada, announced today the Phase 3 HYPERION study evaluating WINREVAIR (sotatercept-csrk) versus placebo (both in combination with background ...
Morningstar4d
Merck Announces Decision to Stop Phase 3 HYPERION Trial Evaluating WINREVAIR™ (sotatercept-csrk) Early and Move to Final Analysis
Robust evidence of the clinical benefit of WINREVAIR demonstrated in the STELLAR and ZENITH studies resulted in a loss of clinical equipoise in the HYPERION study Merck (NYSE: MRK), known as MSD ...